Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

Free Publication Certificate

Vol. 7, Issue 7 (2018)

Roflumilast: an experience of its use in the treatment of severe COPD

Author(s):
Valentyna Goncharuk, Iryna Savelikhina and Kseniia Ostrovska
Abstract:
Chronic obstructive pulmonary disease (COPD) is a pathologic pulmonary condition characterized by expiratory airflow obstruction due to emphysematous destruction of the lung parenchyma and remodeling of the small airways. COPD is now recognised to be a condition of global importance because of high morbidity and risk of premature death of millions of people. Chronic inflammation and exacerbations play a central role in the progression of the disease. Roflumilast – a phosphodiesterase-4 (PDE4) inhibitor, through selective inhibition of the PDE4 enzyme, roflumilast prevents the breakdown of cyclic AMP, which plays an important role in regulating inflammatory cell activity.
Pages: 218-220  |  813 Views  73 Downloads


The Pharma Innovation Journal
How to cite this article:
Valentyna Goncharuk, Iryna Savelikhina, Kseniia Ostrovska. Roflumilast: an experience of its use in the treatment of severe COPD. Pharma Innovation 2018;7(7):218-220.

Call for book chapter